Method of prostaglandin synthesis

Details Method of prostaglandin synthesis Method of prostaglandin synthesis

1997-10-31

2002-02-05

Gerstl, Robert (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carboxylic acid esters

C562S500000

Reexamination Certificate

active

06344581

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates to the use of prostaglandins and prostaglandin analogues for the treatment of glaucoma and ocular hypertension. As used herein, the terms “prostaglandin” and “PG” shall refer to prostaglandins and derivatives and analogues thereof, except as otherwise indicated by context.
Naturally-occurring prostaglandins, including prostaglandins of the F series (such as PGF
2&agr;
), the E series (such as PGE
2
) and the D series (such as PGD
2
), are known to lower intraocular pressure (IOP) after topical ocular instillation, but can cause marked conjunctival hyperemia and/or inflammation with a number of associated side effects. There have been many attempts to synthesize prostaglandin derivatives which are more effective at lowering IOP and/or which have reduced side effects. Such attempts have been made by Stjernschantz et al. (WO 90/02553) and Woodward (U.S. Pat. No. 5,093,329) to selectively reduce or eliminate the side effects while maintaining the IOP-lowering effect.
SUMMARY OF THE INVENTION
It has now been unexpectedly discovered that certain 9-halo-13,14-dihydroprostaglandins are significantly more effective in lowering IOP than other, known prostaglandins. In particular, the compounds of the present invention have unexpectedly been found to lower IOP between about 40 to 50%, with greatly reduced side effects, particularly with respect to hyperemia.


REFERENCES:
patent: 3931289 (1976-01-01), Bundy
patent: 3954881 (1976-05-01), Bowler
patent: 3996267 (1976-12-01), Bundy
patent: 4444788 (1984-04-01), Skuballa et al.
patent: 4454339 (1984-06-01), Skuballa et al.
patent: 4789685 (1988-12-01), Skuballa et al.
patent: 5004752 (1991-04-01), Raduechel et al.
patent: 5079259 (1992-01-01), Skuballa et al.
patent: 5093329 (1992-03-01), Woodward
patent: 5204371 (1993-04-01), Skuballa et al.
patent: 6015922 (2000-01-01), Conrow
patent: 6040468 (2000-03-01), Conrow
patent: 4229048 (1994-03-01), None
patent: 4229050 (1994-03-01), None
patent: 4229051 (1994-03-01), None
patent: 253094 (1988-01-01), None
patent: 0 295 880 (1988-12-01), None
patent: 0 299914 (1989-01-01), None
patent: 0 561073 (1993-09-01), None
patent: 1553710 (1979-10-01), None
patent: WO 9002553 (1990-03-01), None
Okamoto et al., “A New Efficient Synthesis of the Biologically Potent PGD2-Analogue ZK118182”Tetrahedron:Asymmetry3(12):1525-1528 (1992).
Shibasaki et al., “A New Method for the Conversion of Aldehydes (RCH2CHO) to Acetylenes (RC≡CH) Via 1-Alkenylstannanes. Application to the Synthesis of 9(O)-Thia-&Dgr;6-PGI1”Tetrahedron Letters23(44):4607-4610 (1982).
Braun, et al., “Effect of ZK 110.841 on Cerebral Vascular Contraction and TXA2-Release Caused by Thrombin-Stimulated Platelets,”Archives of Pharmacology, 339 Suppl:R37(148) (1989).
Buchmann et al., “Synthesis of a Chemical and Metabolically Stable and Biologically Potent PGD2-Analogue,”TetrahedronLetters, 31(24):3425-3428 (1990).
Buchmann et al, Synthesis of a Chemically and Metabolically Stable and Biologically Potent PGD2-AnalogChemical Abstracts113:211633 (1990).
Goh et al., “Effect of Topical Prostaglandins D2on the Aqueous Humor Dynamics in Rabbits”Graefe's Arch. Clin. Exp. Ophthalmol., 227:476-481 (1989).
Nakajima et al., “Effects of Prostaglandin D2and its Analogue, BW245C,.on Intraocular Pressure in Humans”Graefe's Arch. Clin. Exp. Ophthalmol., 229-411-413 (1991).
“New Research Drug DLO/8149” Drug License Opportunities (IMSWORLD Publications) (Jun. 25, 1990).
Ney, “Potent Inhibition of FMLP-Induced Neutrophil Activation by the PGD2Analogue ZK 110.841,”Archives of Pharmacology, 339 Suppl:R38 (150)(1989).
Thierauch et al., “Stable 9&bgr; -Or 11&agr;-Halogen-15-Cyclohexyl-Prostaglandins With High Affinity to the PGD2-Receptor”Prostaglandins, 35:6:855-868 (1988).
Thierauch et al., “Stable 9&bgr;- Or 11&agr;-Halogen-15-Cyclohexyl-Prostaglandins With High Affinity to the PGD2-Receptor”Advances in Prostaglandin, Thromboxane and Leukotriene Research, 19:655-658 (1989).
Woodward et al., “Studies on the Ocular Pharmacology of Prostagladin D2”Invest. Ophthalmol. Vis. Sci., 31:138-146 (1990).

Affiliated with

Also associated with

Rating

Method of prostaglandin synthesis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of prostaglandin synthesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of prostaglandin synthesis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2958601